Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer

Prostate cancer is one of the most common cancers that affect males. Metastatic prostate cancer is treated at first with androgen deprivation therapy (ADT) and androgen receptor pathways inhibitors (ARPI). It is initially responsive to these treatments, but overtime it progresses from being hormone-sensitive to become castrate resistant, which leads to poorer outcomes. There have been other therapies that have been approved for treatment of metastatic castrate-resistant prostate cancer (mCRPC), but there are high-risk features such as high tumor burden, shorter time from diagnosis to metastatic disease, and presence of metastases that cause poor outcomes, with the overall survival being less than one year. Zanzalintinib is a new drug that targets the receptors involved with cancer cell growth. The purpose of this study is to find out if Zanzalintinib is an effective treatment for participants with mCRPC with soft tissue or visceral metasteses who have progressed on prior ARPI treatments.